会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明授权
    • Substituted orally effective ION chelators related to deferoxamine
    • 与去铁胺相关的替代口服有效的ION螯合剂
    • US5550161A
    • 1996-08-27
    • US144664
    • 1993-10-28
    • Donald E. Green
    • Donald E. Green
    • A61K31/16A61K31/22A61K31/23A61K31/295C07C233/00C07C259/06
    • A61K31/295A61K31/16A61K31/22A61K31/23C07C233/00C07C259/06
    • Compounds are described of the general formula: ##STR1## wherein: R.sub.1 is acyl of the formula --C(=O)-R.sub.5 : R.sub.2, R.sub.3, R.sub.4, R.sub.6, R.sub.7 and R.sub.8 are each selected from the group consisting of hydrogen and acyl of the formula:--C(=O)-R.sub.5wherein R.sub.5 is selected from the group consisting of alkyls, substituted alkyls, alkenyls, substituted alkenyls, cycloalkyls, substituted cycloalkyls, arylalkylenes, substituted arylalkylenes, alkylenecycloalkyls, alkylene substituted cycloalkyls, alkynyls, substituted alkynyls, aryls and substituted aryls, wherein R.sub.2, R.sub.3 and R.sub.4 are selected such that at least one of R.sub.2, R.sub.3 and R.sub.4 is an acyl.When R.sub.2, R.sub.3 and R.sub.4 include one or more acyls that are not identical to the acyl of R.sub.1, these compounds of formula I are novel compounds. The invention also includes processes to produce the compounds of formula I.Compounds of formula I complex and/or chelate tissue tri-valent ions, especially iron and aluminum (Fe.sup.+++, Al.sup.+++), when administered to a human being, and are therefore useful in therapy in the treatment of diseases in which tissue ion levels in the body have increased or toxic levels. These iron-related diseases include, for example, thalassemia major, sideroachrestic anemic, BlacKfan-Diamond anemia, aplastic anemia, sickle cell anemia, hemolytic anemias and hemosiderosis brought about by multiple blood transfusions including treatment for the anemia accompanying conditions requiring kidney dialysis. Aluminum-related diseases or conditions include Alzheimer's disease, senile dementia and dialysis encephalopathy.
    • 化合物描述于下列通式:其中:R 1是式-C(= O)-R 5的酰基:R 2,R 3,R 4,R 6,R 7和R 8各自选自 由氢和下式的酰基组成:-C(= O)-R 5,其中R 5选自烷基,取代的烷基,烯基,取代的烯基,环烷基,取代的环烷基,芳基亚烷基,取代的芳基亚烷基,亚烷基环烷基,亚烷基取代的 环烷基,炔基,取代的炔基,芳基和取代的芳基,其中R2,R3和R4被选择为使得R 2,R 3和R 4中的至少一个是酰基。 当R 2,R 3和R 4包括一个或多个与R 1的酰基不相同的酰基时,式I化合物是新化合物。 本发明还包括制备式I化合物的方法。当给予人类时,式I化合物复合和/或螯合组织三价离子,特别是铁和铝(Fe +++,Al +++)),因此可用于 治疗治疗身体中组织离子水平升高或有毒水平的疾病。 这些与铁有关的疾病包括,例如,地中海贫血症,铁血性贫血,BlacKfan-Diamond贫血,再生障碍性贫血,镰状细胞性贫血,多种输血引起的溶血性贫血和含铁血黄素沉着症,包括治疗需要肾透析的贫血症。 与铝有关的疾病或病症包括阿尔茨海默病,老年性痴呆和透析性脑病。